Search research articles
Contact Us
Filters
Showing results (211-220 of 227) with videos related to
Page
of 23
Sort By:
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Cancer Research
|
May 6, 2004
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Bennett Kaufman, Orit Scharf, Jeffrey Arbeit, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Melanoma Research
|
March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 227) with videos related to
Sort By:
Page
of 23
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Cancer Research
|
May 6, 2004
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
Bennett Kaufman, Orit Scharf, Jeffrey Arbeit, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Joseph W Kim, Rana R McKay, Marc R Radke, et al.
Melanoma Research
|
March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2023
The New NCI Precision Medicine Trials
Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Christina Yap, Olga Solovyeva, Johann de Bono, et al.
BMJ (Clinical Research Ed.)
|
October 20, 2023
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Christina Yap, Jan Rekowski, Moreno Ursino, et al.
Page
of 23